# CAN SLIM Progress Board

Last updated: 2026-09-14

Frozen quantitative v1 remains research-complete but not production-ready. FWD1 and EXH2 continue unchanged. The theory-fidelity path now has frozen contracts through #52. #43 remains the current stock-level lifecycle arbiter; #44 is climax/exhaustion evidence-only; #45/#46 form the portfolio-level CAN SLIM `M` state-to-exposure path; #47-#50 define and operate the major-index production path; #51 defines the leadership/weakening evidence contract; #52 audits its broad-market source boundary.

## Repository boundary for #33

**Canonical #33 implementation and P8 morphology validation live in `azharmz/ussy-oneil-patterns`.** Frozen production contract: `oneil-pattern-output-v2` with only `FLAT_BASE`, `DOUBLE_BOTTOM`, `CUP_WITHOUT_HANDLE`, and `CUP_WITH_HANDLE`. P6 advanced patterns remain excluded and frozen.

## Theory Fidelity / v2 path

| # | Workstream | Status |
|---:|---|---|
| 25 | Theory Fidelity Audit | **COMPLETE** |
| 26 | Proper-base definitions | **COMPLETE** |
| 27 | Pivot / buy-point definition | **COMPLETE** |
| 28 | Breakout + volume confirmation | **COMPLETE** |
| 29 | RS / leadership fidelity | **COMPLETE** |
| 30 | C/A/S/I/M role fidelity | **COMPLETE** |
| 31 | Sell / risk-management fidelity | **COMPLETE** |
| 32 | Theory-faithful candidate specification | **COMPLETE / FROZEN v1** |
| 33 | O'Neil Pattern Recognition Engine | **CORE COMPLETE / FROZEN — P8 CONDITIONAL PASS** |
| 34 | Theory-faithful candidate generator | **COMPLETE / FROZEN v1** |
| 35 | New-candidate validation | **COMPLETE / FROZEN — CONDITIONAL PASS** |
| 36 | Execution / entry research | **BASELINE FROZEN / DIAGNOSTIC COMPLETE / PRIMARY PERFORMANCE VALIDATION BLOCKED_ON_ELIGIBLE_POPULATION** |
| 37 | Sell / risk execution semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 38 | Technical deterioration evidence | **EVIDENCE LAYER COMPLETE / FROZEN v1** |
| 39 | Weekly aggregation / 10-week evidence | **WEEKLY AGGREGATION + 10W EVIDENCE COMPLETE / FROZEN v1** |
| 40 | Technical deterioration action semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 41 | Position lifecycle / exit arbiter | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 42 | Round-trip sell action semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 43 | Position lifecycle / exit arbiter v2 | **IMPLEMENTATION COMPLETE / FROZEN v2** |
| 44 | Climax / exhaustion evidence | **EVIDENCE LAYER COMPLETE / FROZEN v1** |
| 45 | Market exposure action semantics | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 46 | Market state evidence / classification | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 47 | Market input data contract | **IMPLEMENTATION COMPLETE / FROZEN v1** |
| 48 | Major index source audit | **SOURCE AUDIT COMPLETE — YAHOO/YFINANCE APPROVED FOR INITIAL PRODUCTION INPUT v1** |
| 49 | Production market index publisher | **PRODUCTION WIRING COMPLETE / LIVE v1** |
| 50 | Production market-state consumer | **PRODUCTION CONSUMER COMPLETE / LIVE v1** |
| 51 | Market leadership / weakening evidence | **EVIDENCE CONTRACT COMPLETE / PRODUCTION BOOLEAN SOURCE DEFERRED** |
| 52 | PIT broad-market leadership source audit | **SOURCE AUDIT COMPLETE / NO PRODUCTION BOOLEAN SOURCE APPROVED** |

## Current canonical architecture

```text
STOCK
#33 Pattern → #34 Candidate → #35 Validation → #36 Entry
→ OPEN POSITION
→ #37 Capital Protection / #40 Technical Deterioration / #42 Round-Trip
→ #43 Stock Lifecycle Arbiter → CLOSED POSITION

#44 Climax/Exhaustion = evidence sidecar only

GENERAL MARKET / CAN SLIM M
#49 production major-index data
NASDAQ_COMPOSITE(^IXIC) / SP500(^GSPC) / DJIA(^DJI)
→ #50 production consumer
→ frozen #46 Market State Classification
↑
#51 Leadership / Weakening Evidence contract
↑
#52 broad-market source audit (production boolean source still deferred)
→ #45 Portfolio Exposure Action
→ target exposure band E0..E4
```

## #34–#35 candidate and validation state

Frozen candidate stages: `BASE_RECOGNIZED → PIVOT_DEFINED → PIVOT_CROSSED → BREAKOUT_CONFIRMED → CANSLIM_ELIGIBLE`.

#34 final verification `34758050282` → **SUCCESS, 9 tests**. #35 canonical historical run `34763920536` produced 265,642 observations with zero V35-A/B/C findings and a frozen 60-case corpus. Independent source-evidence audit `34765922653` → **SUCCESS**, C/A/L/M 60/60 MATCH and PIT violations = 0. #35 remains `CONDITIONAL PASS` solely with upstream #33 morphology debt preserved.

## #36–#43 stock lifecycle

#36 canonical T+1-open execution remains frozen; primary performance validation remains `BLOCKED_ON_ELIGIBLE_POPULATION` because canonical #35 has 0 `CANSLIM_ELIGIBLE` observations.

#37 capital protection, #40 technical deterioration and #42 round-trip are the three frozen executable stock-level exit channels. #43 v2 arbitrates them by earliest causal executable exit, preserving same-session ambiguity/source conflicts rather than inventing an OHLC path.

Canonical validations remain green: #36 `34785545504`; #37 `34787905360`; #38 `34788119495`; #39 `34788414986`; #40 `34789559782`; #41 `34790106465`; #42 `34793348883`; #43 `34796938374`.

## #44 — Climax / Exhaustion Evidence

Contract `44-climax-exhaustion-evidence-v1` remains evidence-only. It records reproducible climax/exhaustion channels without creating a fourth exit. Prior-advance/base-stage context remains unresolved for a canonical action rule. EXH2 remains separate and unchanged. Canonical run `34797449482` → **SUCCESS, 10 passed**.

## #45 — Market Exposure Action

Contract `45-market-exposure-action-v1` remains frozen. Portfolio exposure vocabulary is E0=0-20%, E1=20-40%, E2=40-60%, E3=60-80%, E4=80-100%. Correction maps to E0/block new entries; follow-through permits gradual re-entry; healthy uptrend can raise at most one band; weakening lowers one band. It is portfolio-level and not a stock liquidation rule.

Canonical run `34802432732` / job `103847631050` → **SUCCESS, 12 passed**.

## #46 — Market State Evidence / Classification

Contract `46-market-state-classification-v1` remains frozen. State chronology is `CORRECTION → RALLY_ATTEMPT → FOLLOW_THROUGH_CONFIRMED → UPTREND_HEALTHY → UPTREND_WEAKENING`, with Day-1-low reset, Day-4+ follow-through, >=1.25% close gain and higher volume. Distribution evidence is >=0.20% decline on higher volume, but no universal distribution-count threshold is invented.

Canonical run `34803676270` / job `103851194650` → **SUCCESS, 13 passed**.

## #47 — Market Input Data Contract

Contract `47-market-input-data-contract-v1` freezes canonical major-index identities:

- `NASDAQ_COMPOSITE`
- `SP500`
- `DJIA`

SPY/QQQ/DIA are explicitly forbidden as canonical substitutes. Missing index volume is never imputed. Index identity, provider, source symbol, fetch timestamp and source-contract version are required provenance.

Semantic-validation run `34806193999` / job `103858438691` → **SUCCESS, 13 passed in 0.04s**.

## #48–#50 — Major-index production path

#48 approved Yahoo/yfinance for initial production input v1 for `^IXIC`, `^GSPC`, and `^DJI` after reproducible source audit. This approval is operational and does not claim exchange-official volume equivalence.

#49 publishes immutable major-index run objects and advances `market/indexes/official.json` only after a complete successful publication. First live publication run `34808006835` succeeded.

#50 verifies the official pointer, manifest/object SHA-256 lineage and frozen #47 identity contract, then imports the canonical frozen #46 implementation rather than duplicating it. First live run `34809438828` produced `FOLLOW_THROUGH_CONFIRMED` as of 2026-09-11. Because leadership/weakening booleans remain unresolved, #50 must not promote the state to `UPTREND_HEALTHY` or `UPTREND_WEAKENING` from fabricated evidence.

## #51 — Leadership / Weakening Evidence

Contract `51-market-leadership-weakening-evidence-v1` freezes what acceptable auxiliary market evidence must contain. Broad-market leaders making/approaching new highs with institutional demand may confirm leadership; a majority of valid observed leaders ceasing to make new highs/breaking down together with institutional selling may confirm weakening. Required channels are tri-state and remain `NOT_EVALUABLE` when provenance/evidence is incomplete.

The current USSY/Musaffa universe is explicitly prohibited as a proxy for broad-U.S.-market leadership.

Status: **EVIDENCE CONTRACT COMPLETE / PRODUCTION BOOLEAN SOURCE DEFERRED**.

## #52 — PIT Broad-Market Leadership Source Audit

Contract `52-pit-broad-market-leadership-source-audit-v1` audits candidate source stacks upstream of #51.

Nasdaq Trader `nasdaqlisted.txt` + `otherlisted.txt` are accepted only as a candidate broad-current-U.S.-exchange membership source for prospective immutable snapshots. They do not themselves designate O'Neil-style leaders or provide institutional accumulation/selling evidence.

Broad OHLCV alone is not a leader selector. IBD/MarketSurge leadership lists and ratings are theory-aligned, but no stable permitted machine-readable/PIT-auditable production access contract has yet been established. Therefore no source stack is approved to emit production #51 booleans.

Status: **SOURCE AUDIT COMPLETE / NO PRODUCTION BOOLEAN SOURCE APPROVED**.

## Forward / production boundaries

FWD1 remains LIVE / ACCUMULATING with its existing gate; EXH2 remains separate and prospective. Theory-fidelity findings must not be retrofitted into FWD1/X3/EXH2.

## Active work from here

1. Keep frozen contracts frozen; do not retune semantic thresholds from returns.
2. Primary lifecycle/performance validation remains blocked until a genuine frozen `CANSLIM_ELIGIBLE` population exists.
3. Prospectively archive immutable Nasdaq Trader broad-market membership snapshots in the data layer if continuing the open-data path.
4. Audit whether a permitted machine-accessible IBD/MarketSurge leadership/rating source can satisfy #52 PIT requirements; otherwise preregister a separate open-data leader-selector study before introducing numeric thresholds.
5. Until an approved #52 source stack exists, #50 must continue passing `leadership_confirming=None` and `weakening_confirmed=None`.
6. A future production exposure consumer may translate frozen #45 target exposure into a published E0–E4 portfolio state; it must not conflate portfolio exposure with stock-level sell rules.
7. A canonical climax action remains unauthorized until prior-advance/base-stage context is resolved.
8. Preserve #33 morphology debt, keep P6 out of production, and keep FWD1/EXH2 unchanged.
